Leprosy for medical practitioners and paramedical workers / (Record no. 15299)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02002nam a2200205Ia 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 241023s9999||||xx |||||||||||||| ||und|| |
| 060 ## - NATIONAL LIBRARY OF MEDICINE CALL NUMBER | |
| Classification number | WC 335 |
| Item number | .Y39 1992 |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Yawalkar, S. J. |
| 245 #0 - TITLE STATEMENT | |
| Title | Leprosy for medical practitioners and paramedical workers / |
| Statement of responsibility, etc. | S.J. Yawalkar. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 5th, ed. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Place of publication, distribution, etc. | Basle, Switzerland : |
| Name of publisher, distributor, etc. | Novartis Foundation for Sustainable Development, |
| Date of publication, distribution, etc. | 1992 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource : |
| Other physical details | ill. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Includes bibliographical references. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | When the first edition of this book was published in 1987, leprosy was still a public health problem in 122 countries. The global number of patients was estimated at between 10 million and 12 million. In the past, leprosy was, and in some places continues to be, a stigmatized disease, and those affected were isolated in leprosaria or segregated villages for fear of infection. As a consequence of prejudice and lack of knowledge, leprosy patients were ashamed of their condition and tried to hide the disease -- their only way to escape social repercussions. The consequent lack of treatment or delayed treatment resulted in an increased risk of disabilities, which in turn strengthened and perpetuated the stigma of the disease -- a vicious circle. The development of multidrug therapy (MDT) changed the face of leprosy dramatically. The treatment consists of three drugs, two of which were developed in the research laboratories of Novartis. MDT made it possible to cure patients, interrupt the transmission of leprosy, and thus -- most important for the social perception of the illness -- prevent disabilities. Even patients with the severest form of the disease show visible clinical improvement within weeks of starting treatment. In 1981, the World Health Organization (WHO) recommended MDT as the standard treatment against leprosy. |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Epidemics |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Leprosy |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Leprosy |
| 710 ## - ADDED ENTRY--CORPORATE NAME | |
| Corporate name or jurisdiction name as entry element | Novartis Foundation for Sustainable Development. |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| -- | DMC |
| Koha item type | Books |
| Date last seen | Total checkouts | Full call number | Barcode | Price effective from | Koha item type | Lost status | Damaged status | Not for loan | Withdrawn status | Home library | Current library | Date acquired |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11/06/2024 | WC 335 .Y39 1992 | 17970 | 11/06/2024 | Books | Dow Medical College | Dow Medical College | 11/06/2024 |